“…Using transcriptome analysis, Elabd et al. indicated that the following factors were significantly upregulated in hypoMSCs compared to norMSCs: 1) inflammation modulation, C-X-Cmotif chemokine ligand 5 (CXCL5), and strayfin (SFN); 2) cellular survival, migration, proliferation, glutathione peroxidase 3 (GPX3), LYL1 basic helix-loop-helix family member (LYL1), FES proto-oncogene, tyrosine kinase (FES), sperm-associated antigen 4 (SPAG4), transferrin receptor 2 (TR2), and thioredoxin interacting protein (TXNIP); 3) chondrolysis, cartilage metabolism; keratin 19 (KRT19), BARX homeobox1 (BARX1), MyoD family inhibitor (MDF1), dachsous cadherin-related 1 (DCHS1); and 4) vasculogenesis and angiogenesis, desmin, ras-interacting protein 1 (RASIP1), LYL1, thioredoxin-interacting protein (TXNIP), and FES [16]. In the present study, the levels of SPAG4, BARX1, CKCL5, KRT19, and TXNIP were >4 × , >4 × , >3.8 × , >3.6 × , and >2.5 × higher, respectively, in hypoMSCs than in norMSCs.…”